The Federal Trade Commission has issued a policy statement warning pharmaceutical companies that make and sell brand-name drugs that they could face legal action if they improperly list patents in the FDA’s catalog of “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the “Orange Book.” This policy has been endorsed by the U.S.
Erik Decker, vice president and CISO at Intermountain Health and chair of the Health Sector Council’s Cybersecurity Working Group, discusses the group’s collaboration with the U.S. government to support healthcare data security mandates.
When common medical procedures are performed in a hospital outpatient department (HOPD) rather than a doctor’s office, costs are substantially higher, according to a national analysis of tens of millions of claims.